Positive Modulatory Interactions of NMDA Receptor GluN1/2B Ligand Binding Domains Attenuate Antagonists Activity

Simple item page
dc.contributor.authorBledsoe, Douglas N.en
dc.contributor.authorTamer, Ceyhunen
dc.contributor.authorMesic, Ivanaen
dc.contributor.authorMadry, Christianen
dc.contributor.authorKlein, Bradley G.en
dc.contributor.authorLaube, Bodoen
dc.contributor.authorCosta, Blaise M.en
dc.contributor.departmentBiomedical Sciences and Pathobiologyen
dc.contributor.departmentSchool of Neuroscienceen
dc.date.accessioned2019-10-31T14:31:25Zen
dc.date.available2019-10-31T14:31:25Zen
dc.date.issued2017-05-09en
dc.description.abstractN-methyl D-aspartate receptors (NMDAR) play crucial role in normal brain function and pathogenesis of neurodegenerative and psychiatric disorders. Functional tetra-heteromeric NMDAR contains two obligatory GluN1 subunits and two identical or different non-GluN1 subunits that include six different gene products; four GluN2 (A-D) and two GluN3 (A-B) subunits. The heterogeneity of subunit combination facilities the distinct function of NMDARs. All GluN subunits contain an extracellular N-terminal Domain (NTD) and ligand binding domain (LBD), transmembrane domain (TMD) and an intracellular C-terminal domain (CTD). Interaction between the GluN1 and co-assembling GluN2/3 subunits through the LBD has been proven crucial for defining receptor deactivation mechanisms that are unique for each combination of NMDAR. Modulating the LBD interactions has great therapeutic potential. In the present work, by amino acid point mutations and electrophysiology techniques, we have studied the role of LBD interactions in determining the effect of well-characterized pharmacological agents including agonists, competitive antagonists, and allosteric modulators. The results reveal that agonists (glycine and glutamate) potency was altered based on mutant amino acid sidechain chemistry and/or mutation site. Most antagonists inhibited mutant receptors with higher potency; interestingly, clinically used NMDAR channel blocker memantine was about three-fold more potent on mutated receptors (N521A, N521D, and K531A) than wild type receptors. These results provide novel insights on the clinical pharmacology of memantine, which is used for the treatment of mild to moderate Alzheimer's disease. In addition, these findings demonstrate the central role of LBD interactions that can be exploited to develop novel NMDAR based therapeutics.en
dc.description.notesThis work was funded by Max Plank Society Research fellowship and One Health Grant (#10243) from the Edward Via College of Osteopathic medicine and Virginia-Maryland College of Veterinary Medicine funded to BC and BK.en
dc.description.sponsorshipMax Plank Society Research fellowship [10243]; Edward Via College of Osteopathic medicine; Virginia-Maryland College of Veterinary Medicineen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.3389/fphar.2017.00229en
dc.identifier.issn1663-9812en
dc.identifier.other229en
dc.identifier.pmid28536523en
dc.identifier.urihttp://hdl.handle.net/10919/95222en
dc.identifier.volume8en
dc.language.isoenen
dc.publisherFrontiersen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectNMDA receptoren
dc.subjectLigand Binding Domain (LBD)en
dc.subjectcompetitive antagonistsen
dc.subjectmemantineen
dc.subjectinterfaceen
dc.titlePositive Modulatory Interactions of NMDA Receptor GluN1/2B Ligand Binding Domains Attenuate Antagonists Activityen
dc.title.serialFrontiers in Pharmacologyen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.dcmitypeStillImageen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fphar-08-00229.pdf
Size:
1019.77 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Scholarly Works, Biomedical Sciences and Pathobiology
Scholarly Works, School of Neuroscience